复星医药:BioNTech将向中国大陆供应不少于1亿剂新冠疫苗产品
uSMART盈立智投12月16日消息,周三港股盘前,复星医药发布公告称,,于2020年12月15日,BioNTech Manufacturing GmbH,为BioNTech的附属公司(「BioNTech Manufacturing」)、复星医药产业及BioNTech就有关BioNTech Manufacturing向其于中国大陆供应新冠疫苗产品订立供货协议(「供货协议」)。
根据供货协议,在新冠疫苗产品获得中国大陆上市批准且复星医药产业根据供应协议下达相应订单的情况下,BioNTechManufacturing承诺于2021年向中国大陆供应不少于1亿剂新冠疫苗产品。
点击可跳转阅读《复星医药自愿公告》原文件PDF。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.